Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

Table 2 Clinical characteristics of the patients with no subclinical proximal tubulopathy at on day 0

	Global population (n = 138); median (Q1; Q3); (n) (min-max)	ETV group; (n = 28); median (Q1; Q3); (n) (min-max)	Naive group; (n = 84); median (Q1; Q3); (n) (min-max)	TDF group; (n = 26); median (Q1; Q3); (n) (min-max)	P value; ETV vs naive	P value; TDF vs naive
Phosphatemia, mmoL/L	1.1 (1.0; 1.2); (n = 135); (0.6-1.4)	1.1 (1.0; 1.1); (n = 26); (0.9-1.3)	1.0 (1.0; 1.2); (n = 83); (0.7-1.4)	1.0 (0.9; 1.2); (n = 26); (0.6-1.2)	0.401	0.981
Plasma creatinine, μmoL/L	73 (58; 85); (n = 137); (37.5-114.9)	78.4 (66; 84); (n = 28); (51-114.9)	71 (58; 87); (n = 83); (37.5-113)	76.9 (57.5; 87); (n = 26); (38-98)	0.232	0.772
eGFR (MDRD), mL/min/1.73 m²	94.5 (82.6; 107.6); (n = 137); (58.6-169.1)	91 (84.2; 101); (n = 28); (62.7-141.3)	94.8 (80.7; 108.1); (n = 83); (58.6-151.1)	95.4 (84.3; 108.4); (n = 26); (70.2-169.1)	0.372	0.652
25(OH)D3, ng/mL	15.9 (9.9; 22.2); (n = 130); (3.1-55.2)	16.8 (12.6; 24.8); (n = 26) (5-55.2)	14.8 (9.4; 21); (n = 81); (4-42.1)	15.3 (9.8; 22.7); (n = 23); (3.1-36.9)	0.272	0.952
TmPi/eGFR, mmoL/L	1 (0.9; 1.1); (n = 181); (0.4-1.9)	1 (0.9; 1.2); (n = 34); (0.7-1.8)	1 (0.9; 1.1); (n = 111); (0.4-1.9)	1 (0.8; 1.2); (n = 36); (0.6-1.5)	0.242	0.862
FEUA, %	5.8 (4.5; 7.1); (n = 112); (2.2-9.7)	5.9 (4.7; 7.5); (n = 23); (2.7-9.1)	5.8 (4.4; 7); (n = 69); (2.2-9.3)	5.5 (4.5; 6.7); (n = 20); (3.8-9.7)	0.641	0.951

¹Student’s test.

²Mann-Whitney test. 25(OH)D3: 25-hydroxyvitamin D3; eGFR: Estimated glomerular filtration rate; ETV: Entecavir; FEUA: Fractional excretion rate of uric acid; Max: Maximum; Min: Minimum; Q1: First quartile; Q3: Third quartile; TDF: Tenofovir disoproxil.